Ardsley Advisory Partners LP Buys 119,050 Shares of Indivior PLC (NASDAQ:INDV)

Ardsley Advisory Partners LP increased its stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 11.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,200,000 shares of the company's stock after buying an additional 119,050 shares during the quarter. Indivior comprises approximately 2.4% of Ardsley Advisory Partners LP's investment portfolio, making the stock its 5th biggest holding. Ardsley Advisory Partners LP owned 0.87% of Indivior worth $14,916,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rathbones Group PLC boosted its position in Indivior by 11.6% during the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock worth $183,000 after purchasing an additional 1,483 shares in the last quarter. Stifel Financial Corp lifted its stake in Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock valued at $158,000 after buying an additional 2,450 shares in the last quarter. PDT Partners LLC lifted its holdings in Indivior by 4.7% in the 4th quarter. PDT Partners LLC now owns 57,520 shares of the company's stock valued at $715,000 after purchasing an additional 2,596 shares in the last quarter. Clark Estates Inc. NY grew its stake in Indivior by 1.3% during the 4th quarter. Clark Estates Inc. NY now owns 257,400 shares of the company's stock valued at $3,199,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Indivior during the 4th quarter worth approximately $56,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Stock Down 2.6 %

NASDAQ INDV traded down $0.30 during trading on Thursday, hitting $11.18. The stock had a trading volume of 375,769 shares, compared to its average volume of 988,724. The company has a market capitalization of $1.54 billion, a PE ratio of -31.94 and a beta of 0.98. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $18.59. The firm has a 50 day moving average price of $9.92 and a 200 day moving average price of $10.50.

Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The firm had revenue of $266.00 million during the quarter, compared to analysts' expectations of $240.13 million. On average, sell-side analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Piper Sandler cut their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. Rodman & Renshaw began coverage on shares of Indivior in a research report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.